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Abstract
Background: Uterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which
carry an extremely poor prognosis. We evaluated the expression levels of EpCAM and the in vitro activity of
solitomab, a bispecific single-chain antibody construct which targets epithelial-cell-adhesion-molecule (EpCAM) on
tumor cells and also contains a CD3 binding region, against primary uterine and ovarian CS cell lines.
Methods: EpCAM expression was evaluated by flow cytometry in a total of 5 primary CS cell lines. Sensitivity to
solitomab-dependent-cellular-cytotoxicity (ADCC) was tested against the panel of primary CS cell lines expressing
different levels of EpCAM in standard 4 h 51Cr release-assays. The proliferative activity, activation, cytokine secretion
(i.e., Type I vs Type II) and cytotoxicity of solitomab in autologous tumor-associated-T cells (TAL) in the pleural fluid
of a CS patient were also evaluated by CFSE and flow-cytometry assays.
Results: Surface expression of EpCAM was found in 80.0 % (4 out of 5) of the CS cell lines tested by flow cytometry.
EpCAM positive cell lines were found resistant to NK or T-cell-mediated killing after exposure to peripheral blood
lymphocytes (PBL) in 4-h chromium-release assays (mean killing ± SEM = 1.1 ± 1.6 %, range 0–5.3 % after incubation of
EpCAM positive cell lines with control BiTE®). In contrast, after incubation with solitomab, EpCAM positive CS cells
became highly sensitive to T-cell-cytotoxicity (mean killing ± SEM of 19.7 ± 6.3 %; range 10.0-32.0 %; P < 0.0001). Ex vivo
incubation of autologous TAL with EpCAM expressing malignant cells in pleural effusion with solitomab, resulted in a
significant increase in T-cell proliferation in both CD4+ and CD8+ T cells, increase in T-cell activation markers (i.e., CD25
and HLA-DR), and a reduction in number of viable CS cells in the exudate (P < 0.001).
Conclusions: Solitomab may represent an effective treatment for patients with recurrent/metastatic and/or chemo-
resistant CS overexpressing EpCAM.
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Introduction
Gynecological carcinosarcomas (CS), also known as
Malignant Mixed Mullerian Tumors (MMMT), are rare
biphasic tumors that most commonly arise in the uterus
and ovaries [1]. Histologically, the carcinomatous compo-
nent may include endometrioid, serous, clear cell,
squamous or mucinous differentiation or may be undiffer-
entiated. CS are classified on the basis of the nature of
their mesenchymal elements as "homologous" when mes-
enchymal components differentiate towards tissues
physiologically native to the primary site (e.g. leiomyosar-
coma, fibrosarcoma and endometrial stromal sarcoma), or
as “heterologous” when they contain mesenchymal com-
ponents that are physiologically foreign to the primary site
(e.g. chondrosarcoma, osteosarcoma, rhabdomyosarcoma
and liposarcoma). While the pathogenesis of CS remains
under debate, an increasing body of evidence supports the
origin of both elements from a common epithelial cell that
undergoes sarcomatous dedifferentiation, rather than two
independent progenitors [2–5]. While CS comprise only a
small percentage (i.e., 1 to 5 %) of ovarian and uterine can-
cers, the overall 5 year survival for ovarian and uterine CS
patient remains a dismal 24 % and 36 %, respectively [1].
The discovery of novel diagnostic and therapeutic markers
against this aggressive subset of gynecological tumors re-
mains a high priority.
Overexpression of epithelial cell adhesion molecule-1
(EpCAM), also known as TROP-1 or TACSTD1, is a
known poor prognostic biomarker across a large number
of carcinomas and carcinosarcomas [4, 5]. EpCAM, a 39
to 42 kd protein, consists of three domains including; an
extracellular domain with 2 epidermal growth factor-like
repeats, a transmembrane domain, and a short 26 amino
acid cytoplasmic domain. EpCAM promotes cell adhe-
sion and is expressed at low levels on different various
epithelia. It is predominantly expressed in the basolateral
and intercellular surface of simple, pseudo-stratified, and
transitional epithelia as well as most epithelial tissues in
the female genital tract [6]. EpCAM is known to play an
important role in multiple cell functions including cell
migration, cell signaling, differentiation, and prolifera-
tion. High levels of expression on the cell surface of
multiple human carcinomas makes EpCAM an attractive
target for immunotherapy [7]. The discovery of EpCAM
(CD326) expression in a number of solid tumors led to
the development of Solitomab (MT110, AMG 110)
which is an EpCAM/CD3-bispecific single-chain anti-
body construct [8]. Solitomab acts by engaging resting
polyclonal CD8+ and CD4+ T cells for highly potent
redirected lysis of target tumor cells that express
EpCAM. Solitomab’s antitumor activity in preclinical
EpCAM positive ovarian tumor xenograft models has
shown promise. In the current study, we have used flow
cytometry and q-Real-time-PCR to evaluate EpCAM
expression in primary carcinosarcomas cell lines and ex-
plored for the first time the potential of solitomab, an
EpCAM/CD3 BiTE®, as a novel therapeutic strategy
against carcinosarcoma cell lines and un-manipulated
malignant tumor cells isolated from malignant pleural
fluid of a patient. Our results demonstrate impressive
solitomab antitumor activity against carcinosarcoma cell
lines and tumor cells in pleural fluid from patients with
gynecologic carcinosarcomas.
Methods
Patients and sample processing
All patients signed an informed consent form according
to institutional guidelines and approval for this in vitro
study was obtained from the institutional review board. A
total of five primary carcinoma cell lines [i.e., two primary
uterine carcinosarcoma cell lines (SARARK-1 and
SARARK-9) and three primary ovarian carcinosarcoma
cell lines (SARARK-3, SARARK-6 and SARARK-7)] were
established after sterile processing of surgical biopsy speci-
mens, as described previously [9]. Briefly, tumor tissue
was mechanically minced to portions no larger than 1 to
3 mm3 in an enzyme solution made of 0.14 % collagenase
type I (Sigma) and 0.01 % DNase (Sigma, 2000 KU/mg) in
RPMI 1640, and incubated in the same solution in a mag-
netic stirring apparatus for an hour at room temperature.
Enzymatically dissociated cells were then washed twice in
RPMI 1640 with 10 % fetal bovine serum and maintained
in RPMI supplemented with 10 % fetal bovine serum,
200 μg/ml of penicillin and 200 μg/ml of streptomycin at
37 °C, 5 % CO2 in 75 cm2 tissue culture flasks or Petri
dishes (Corning). After seeding on plasticware for 48–72
h, nonadherent cells and contaminant inflammatory cells
were gently removed from the culture by multiple wash-
ings with PBS. Both primary uterine carcinosarcoma cell
lines were established from biopsies of the uterus of
chemotherapy naïve patients at the time of the primary
staging surgery, while all primary ovarian carcinosarcoma
cell lines were obtained from the biopsy of metastatic sites
of disease in patients harboring recurrent, chemotherapy-
resistant disease. In all primary ovarian carcinosarcoma
cell lines cases, the high in vivo resistance to multiple
chemotherapy agents was confirmed in vitro by MTT
chemotherapy resistance assays against multiple cytotoxic
agents (data not shown). Primary carcinosarcoma cell
lines were tested for presence of EpCAM by Quantitative
Real-time PCR and by flow cytometry as described below.
An additional tumor sample was collected from a CS pa-
tient with recurrent disease and a large pleural effusion.
The fluid sample was cytologically confirmed to contain a
large number of EpCAM+ carcinosarcoma cells at the
time of a therapeutic thoracentesis. The fresh sample of
pleural fluid was plated into 6-well microtiter plate for
treatment using solitomab and a nonspecific BiTE® control
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antibody construct without prior processing. Cell numbers
and viability were determined by flow cytometry as de-
scribed below. Patient characteristics of all carcinosar-
coma cell lines and the pleural fluid exudate are described
in Table 1.
Ex vivo therapy of malignant pleural fluid sample
Malignant fluid sample was analyzed after ex vivo treat-
ment with solitomab or a control bispecific antibody
construct. Briefly, the malignant fluid sample was plated
in duplicate in 6-well flat microtiter plate. The pleural
fluid was treated with the bispecific antibody construct,
solitomab (Amgen Research Munich GmbH, Munich,
Germany) at a concentration of 1 μg/ml for 7 days. In
control wells, pleural fluid was treated with control
BiTE® huMEC14 also at a concentration of 1 μg/ml. The
effect of solitomab on the malignant tumor cells was
assessed by observation of induction of morphologic
changes and extent of cytotoxicity, as well as, for evi-
dence of T cell activation and induction of cytokine re-
lease as described below.
Quantitative real-time polymerase chain reaction
RNA isolation from all five primary carcinosarcoma cell
lines were performed using TRIzol Reagent (Invitrogen)
according to the manufacturer’s instructions as previously
described. The endogenous control, glyceraldehyde-3-
phosfate dehydrogenase (GAPDH) Assay Hs99999905_ml
(Applied Biosystems, Foster City, CA) was used to
normalize variations in cDNA quantities from different
samples. The comparative threshold cycle (CT) method
was used for the calculation of amplification fold as speci-
fied by the manufacturer. Quantitative real-time PCR
(qRT-PCR) was done with a 7500 Real-time PCR System
using the protocols recommended by the manufacturer
(Applied Biosystems) to evaluate expression of EpCAM in
all samples. Briefly, 5 μg of total RNA from each sample
was reverse transcribed using SuperScript III first-strand
cDNA synthesis (Invitrogen). Five μl of reverse transcribed
RNA samples (from 500 μl of total volume) were ampli-
fied by using the TaqMan Universal PCR Master Mix (Ap-
plied Biosystems) to produce PCR products specific for
EpCAM. The CT method (Applied Biosystems) was used
to determine gene expression in each sample relative to
the value observed in a control cell line known to express
EpCAM, using GAPDH (Assay ID Hs99999905_ml) RNA
as internal controls.
Flow cytometry
Characterization of EpCAM expression in primary uterine
and ovarian carcinosarcoma cell lines was performed by
FACS analysis. The anti-human EpCAM-PE antibody
clone 1B7 (eBioscience) was used for flow cytometry stud-
ies. The IgG1-PE antibody (BD Biosciences) was used as
antibody isotype control for the anti-EpCAM antibody.
Moreover a Human recombinant IgG1 anti-EpCAM
monoclonal antibody (mAb) MT201 (Micromet AG) was
used for flow cytometry studies. Briefly, cell lines were
stained with MT201 (Micromet AG). The chimeric anti-
CD20 mAb rituximab (Rituxan, Genentech, San
Francisco, CA) was used as a control. A goat antihuman
F(ab′)2 immunoglobulin (BioSource International,
Camarillo, CA) was used as a secondary reagent. Analysis
was conducted with FACScalibur flow cytometer with Cell
Quest software (Becton Dickinson, Franklin lakes, NJ).
T cell stimulation assay
Solitomab induced T cell activation was measured by de-
tecting CD25 protein surface expression and HLA-DR
expression on CD8+ and CD4+ T cells by FACS.
Table 1 Patient characteristics and EpCAM Protein Expression by Flow Cytometry and by qReal-Time PCR in carcinosarcoma cell
lines
Cell Line Histology Age Race FIGO Stage Primary site Percentage EpCAM-Positive Cells MFI Avg dCt qReal-Time PCR
ES SC
SARARK-1 Homologous ESS 70 AA* IC Uterus 10.6 13.2 17.87
END + CC
SARARK-3 Heterologous CDRS 75 C IIIC Ovary 100 726 3.84
SER
SARARK-6 Homologous CDR 78 C IV/IIB Ovary 100 301.2 3.57
SER
SARARK-7 Heterologous CDRS 55 AA IV Ovary 100 939.9 7.16
CC + SER
SARARK-9 Homologous ESS 66 C IIIC2 Uterus 100 862.6 6.05
SER
*AA African-American, C Caucasian, FIGO International Federation of Gynecology and Obstetrics, EC epithelial component, SC stromal component, END
endometrioid, ESS endometrial stromal sarcoma, CC clear cell, CDR chondroid, CDRS chondrosarcoma, SER serous
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Solitomab mediated stimulation of T cells was calculated
according to the following formula: Percentage of
CD8+/CD25+ expression = [number of CD8+/CD25+
cells/ total number of CD8+ cells] x 100. Similarly,
using the same equation the number of CD8+/HLA-
DR+, CD4+/CD25+ and CD4+/HLA-DR+ expression
was calculated.
Cytokine analysis
The level of solitomab dependent cytokine induction
was compared to the corresponding value of percentage
of cytokine released in the non-specific antibody control
wells. This was performed by treating the solitomab and
control non-specific antibody construct wells with phor-
bol myristate acetate and ionomycin followed by a 3 h
incubation period to allow for lymphocyte stimulation.
Brefeldin A was added and a further incubation for 3 h
occurred in order to enhance intracellular cytokine
staining signals. Cytokine analysis of the supernatants
was performed by FACS analysis after adding anti-CD8-
FITC antibody for surface staining followed by fixation,
permeabilization and intracellular staining with anti-IL-
4-PE antibody and anti-IFN gamma-PE antibody. Solito-
mab mediated release of each of these cytokines was
calculated according to the following exemplary formula:
Percentage of CD8+/IFN gamma containing cells = [num-
ber of CD8+/IFN gamma cells/total number of CD8+ cells]
× 100. Similar calculations were performed for CD4+ T
cells (i.e., gated CD3+/CD8- T cells).
Tests for T cell mediated cytotoxicity
The standard 4-h chromium (51Cr) release assay was
used to measure the cytotoxic reactivity of Ficoll-
Hypaque-separated peripheral blood lymphocytes
(PBLs) from several healthy donors against five carcino-
sarcoma cell lines at effector to target ratios (E:T) of
10:1 and 20:1. The release of 51Cr from target cells was
measured as evidence of tumor cell lysis after exposure
of the tumor cells to a concentration of 1 μg/ml of soli-
tomab. The negative control conditions were the incu-
bation of target cells alone or with PBL without BiTE®
antibody construct. As a positive control condition, 1 %
sodium dodecyl sulfate (SDS) was used to achieve
complete lysis of target cells. The control BiTE®
huMEC14 at 1 μg/ml was used as the negative control
for solitomab in this bioassay. The control BiTE® anti-
body construct shared the CD3 binding arm with soli-
tomab, but otherwise recognizes an herbicide as an
irrelevant antigen instead of recognizing EpCAM. The
percentage cytotoxicity of solitomab was calculated by
the following formula: % cytotoxicity = 100 X (E-S)/T-S),
where E is the experimental release, S is the
spontaneous release by effector cells, T is the maximum
release by target cells lysed with 1 % SDS.
Statistics
The paired t test was used to evaluate the differences in
cellular cytotoxicity levels in primary tumor cell lines
treated with solitomab versus control BiTE® huMEC14.
An increase in T-cell activation and the release of cyto-
kines were analyzed using the t test for paired data. Stat-
istical analysis was performed using SPSS version 18. A
P-value of < 0.05 was considered as the level of statistical
significance.
Results
Epithelial cell adhesion molecule levels in primary
carcinosarcoma cell lines
We used flow cytometry to obtain highly sensitive mea-
surements of EpCAM surface expression in two primary
uterine carcinosarcoma cell lines (SARARK-1 and
SARARK-9) and three primary ovarian carcinosarcoma
cell lines (SARARK-3, SARARK-6 and SARARK-7).
Table 1 depicts the characteristics of the patients from
which the samples were collected and shows the per-
centage of EpCAM positive cells and corresponding
mean fluorescence intensity (MFI) in primary carcino-
sarcoma cell lines by flow cytometry. Among the pri-
mary cell lines, 4 out of 5 (80 %) were found to express
EpCAM in 100 % of the tumor cells. The percentage of
EpCAM-positive cells and EpCAM expression levels
were high in SARARK-3, SARARK-6, SARARK-7 and
SARARK-9. In contrast, low to negligible EpCAM ex-
pression was observed in SARARK-1 cells. EpCAM sur-
face expression was also confirmed by qReal-Time PCR.
As shown in Table 1, good correlation was found be-
tween q-Real-Time PCR and flow cytometry data results.
Carcinosarcoma primary cell lines are resistant to natural
killer (NK) cell activity but sensitive to solitomab-mediated T
cell cytotoxicity
We evaluated all five primary carcinosarcoma cancer
cell lines for their sensitivity to NK and T-cells with
a standard 4-h chromium (51Cr) release assay cytotox-
icity using solitomab (EpCAM BiTE®) at a concentra-
tion of 1 μg/ml, as described previously [10]. The cell
lines were exposed to peripheral blood lymphocytes
collected from multiple healthy donors in several
cytotoxicity assays. In this regard, peripheral blood
lymphocytes typically contain between 20–25 % CD8+
T cells and 10–20 % NK cells (CD56+/CD16+). In
previous titration experiments we found ADCC
against tumor cells to plateau at 1 μg/ml concentra-
tion (10). This concentration was therefore used as
optimal concentration in the cytotoxicity experiments
described below. We found CS cell lines to be highly
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resistant to NK and T-cell-mediated killing when
challenged with PBL at target: effector ratios of 1:10
and 1:20 (ratio 1:20, mean killing ± STDEV, 1.1 ±
1.6 % with range of killing 0–5.3 % after incubation
of EpCAM-positive cell lines with control BiTE®)
(Fig. 1). In contrast, significant killing was detected
against all EpCAM-positive cell lines when challenged
with PBL in the presence of solitomab at a ratio of killing
of 20:1 (i.e., 10.0–32.0 %; mean killing ± STDEV, 19.7 ±
6.3 %; P < 0.0001). As expected, the low EpCAM express-
ing cell line (SARARK-1) demonstrated low to negligible
levels of cytotoxicity when challenged with PBL in the
presence of solitomab (Fig. 1).
Cytotoxicity evaluation in co-cultures of solitomab (EpCAM
BiTE®) and CS tumor-associated lymphocytes
Cytotoxicity was evaluated after co-culturing for 7 days
EpCAM-positive CS tumor cells with solitomab and au-
tologous TALs in a freshly collected pleural exudate fluid
sample (APL13). Anti-EpCAM antibodies were used to
label tumor cells to be counted by flow cytometry and
human recombinant IgG1 anti-EpCAM monoclonal
antibody (mAb) MT201 combined with propidium iod-
ide (PI) for exclusion of dead cells. As shown in Fig. 2,
incubation for 7 days with solitomab significantly de-
creased the number of EpCAM-positive tumor cells in
the freshly collected pleural effusion sample.
Activation of T-lymphocytes by solitomab (EpCAM BiTE®) in
co-cultures with carcinosarcoma cells
Next, we explored whether solitomab is capable of indu-
cing T cell activation in the presence of carcinosarcoma
cells in minimally manipulated pleural fluid samples (i.e.,
APL13). CD8+ T and CD4+ T cells at baseline and after
7-days co-cultures with solitomab were analyzed by flow
cytometry for the expression of the T-cell activation
markers CD25 and HLA-DR. As demonstrated in the
Fig. 3, we found a significant increase in both CD25 and
HLA-DR protein surface expression on CD8+ and CD4+
T cells in the solitomab treated wells when compared to
the wells treated with the control BiTE®. These data are
consistent with our previous results with solitomab in
the ascitic fluid of ovarian cancer patients [10].
Cytokine release accompanying T lymphocyte activation
Next we investigated the level of the solitomab
dependent cytokine induction in PBL when compared to
the cytokine release of PBL stimulated with non-specific
BiTE® control wells in the presence of EpCAM positive
CS. The flow analysis was performed after 7 days of co-
incubation of solitomab with tumor cells and PBLs be-
fore lymphocyte stimulation in the presence of brefeldin
A as described in the Methods section. The analysis by
FACS revealed a significant increase in IFN-gamma pro-
duction in EpCAM+ pleuric fluid exposed to solitomab
when compared to control BiTE® wells in both CD8+ T
and CD4+ T cells, (Fig. 4). In contrast, we were unable
to demonstrate any increase in IL-4 cytokine release in
solitomab exposed pleural fluid T-cells when compared
to wells stimulated with control BiTE®.
Discussion
Carcinosarcomas of gynecologic origin are rare and
comprise 2–5 % of uterine and 1–2 % of ovarian cancers
[1–3]. Although surgical debulking followed by chemo-
therapy is the mainstay of treatment for both uterine
and ovarian CS, the overall 5-year survival is 30 ± 9 %
for all stages, and the recurrence rate after treatment is
extremely high (50–80 %) (1–3). The atypical
Fig. 1 Graph showing antibody-dependent cell-mediated cytotoxicity
for all five CS cell lines in control conditions and with solitomab at two
effector: target ratios. The higher effector: target ratio of 1:20 exhibited
more pronounced cytotoxicity results (EpCAM+ cell lines, ratio 1:10,
p = 6.40731E-10, EpCAM+ cell lines, 1:20, p = 2.10467E-10). In
EpCAM- cell line the difference in cytotoxicity between control
Bite and solitumab was not significant)
Fig. 2 Graph showing the percentage of EpCAM positive viable cell
in patients’ pleura exudate after 7 days incubation with control BiTE®
vs solitomab. EpCAM (p = 2.09378E-06); MT201/P1 (p = 0.001724101)
significant difference
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pathogenesis and poor prognosis of uterine and ovarian
CS, despite aggressive conventional treatment modal-
ities, have inspired us to better understand the molecular
basis of CS in hope of developing novel and effective
treatment modalities.
EpCAM expression has been reported in a number of
different carcinomas [4–7, 11–13]. EpCAM expression
in nonmalignant tissue is low and mostly limited to the
basolateral surface of epithelia [4–7, 11–13]. The physio-
logic location and low level expression of EpCAM in
normal tissues allow for minimal interaction between
these proteins and intravenously administered anti-
EpCAM mAb. EpCAM mAb accessibility data gathered
from studies using mice harboring human xenografts of
EpCAM-expressing syngeneic tumors and normal epi-
thelial tissues support this idea [13]. The differential
expression and accessibility of EpCAM on metastatic/
chemotherapy-resistant CS cells compared to normal tis-
sues make EpCAM an attractive protein that might be
exploited for targeted therapy. As a result patients with
Fig. 3 Upper panel: CD25 and HLA-DR activation marker expression in CD8+ and CD4+ T cells after stimulation of T-lymphocytes exposed to
solitomab vs control BiTE®. A significant increase in CD25 and HLA-DR activation marker expression was consistently detected in both CD8+ or CD4+
T cells (CD8/CD25, CTRL VS BITE, p = 0.00000110594; CD8/HLADR, CTRL VS BITE p = 0.00017812290; CD4/CD25, CTRL VS BITE p = 0.00001948657; CD4/
HLADR, CTRL VS BITE p = 0.00000732741). Lower panel: representative flow cytometry graphic evidencing the increase in the activation marker CD25 in
CD8+ T lymphocytes after stimulation with Solitumab vs control BITE
Fig. 4 Representative IFN-gamma cytokine release after stimulation of
T-lymphocytes exposed to solitomab vs control BiTE®. A significant
increase in IFN-gamma stained cells was consistently detected in both
CD8+ or CD4+ T cells (CD8/INF-gamma, CTRL VS BITE, p = 0.001478197;
CD4/INF-gamma, CTRL VS BITE, p = 7.84945E-06; CD8/IL4, CTRL VS BITE,
p not significant; CD4/IL4, CTRL VS BITE p not significant)
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EpCAM expressing carcinosarcomas refractory to stand-
ard treatments maybe benefit from BiTE®-based
immunotherapy.
BiTE® molecules act through linking tumor cells ex-
pressing EpCAM to CD3 T cell receptors with single-
chain bispecific antibody constructs. Directly linking
CD3 T cell-receptors to tumor cells allow for direct T
cell stimulation and response. This direct response is
not restricted by presence of MHC I, T cell receptor spe-
cificity, antigen presentation, or T cell co-stimulation.
Data presented here support the potential of solitomab,
an EpCAM/CD3 bispecific antibody construct (BiTE®),
as a new therapeutic strategy against chemotherapy-
resistant EpCAM expressing CS.
Cell lines established from patients harboring ad-
vanced and/or chemotherapy resistant carcinosarcoma
were assessed for EpCAM expression as were free tumor
cells and spheroids collected via thoracocentesis from a
patient. EpCAM was overexpressed in the majority of
the primary CS cell lines. These data are similar to data
we previously reported for EpCAM in ovarian cancer
patients [9, 14] as well as TROP-2, another cell-surface
glycoprotein and potential target in CS [15]. Further-
more CS cell lines expressing EpCAM were susceptible
to ADCC when exposed to solitomab. Studies previously
demonstrated the cytotoxic activity of solitomab against
a human colon cancer cell line as well as metastatic
ovarian cancer cells in the presence of PBL [10, 16]. The
data presented here suggest that the cytotoxic potential
of solitomab may be extended to biologically aggressive
and/or highly chemotherapy-resistant to uterine and
ovarian CS cell lines. Solitomab-mediated T cell killing
in the presence of effector cells was dependent on
EpCAM surface expression. Tumor cells were highly
susceptible to T cell mediated killing if EpCAM was
present while negligible cytotoxicity was seen in cell
lines with low level of EpCAM expression.
NK cells are known to play a critical role in the elim-
ination and surveillance of cancer. Interestingly,
EpCAM-positive CS cell lines were highly resistant to
natural killer cytotoxic activity. While in the present
study we did not investigate the mechanisms of resist-
ance to NK cells, efficacy of cancer immunotherapy with
antibodies activating cellular and complement-mediated
cytotoxicity is known to be limited by the overexpression
of multiple membrane-bound complement-regulatory
protein (mCRPs). Consistent with this view, recent data
from our group in uterine serous carcinomas, a subset
of biologically aggressive tumors histologically similar to
CS, demonstrate overexpression of mCRPs CD46, CD55
and CD59 in the majority of the tumors [17].
Importantly, primary CS cell lines in our study were
highly sensitive to solitomab-mediated T cell cytotoxicity
in 4-h 51Cr release assays. Data also show that ex vivo
CS single cell suspensions and tumor spheroids isolated
from the pleural fluid of a CS patient harboring chemo-
therapy resistant disease may also be highly sensitive to
solitomab-mediated cytotoxicity. These results were ob-
tained by culturing freshly collected tumor and tumor
associated lymphocytes ex vivo. After adding solitomab
to the culture, without immune-stimulatory cytokines,
tumor killing was observed. These data suggest that soli-
tomab may be an efficacious treatment for recurrent dis-
ease in vivo.
Our data suggests that solitomab is a potent stimulator
of T cell cytotoxicity even at low effector to target ratios
while simultaneously inducing significant CD8+ and
CD4+ T lymphocyte proliferation. TAL isolated from
the pleural fluid of a heavily pretreated CS patient, and
subsequently exposed to solitomab, increase their pro-
duction of type I cytokine production. The integrity and
size of CS tumor spheroids, found in ex vivo cultures
containing tumor cells expressing EpCAM and autolo-
gous tumor associated lymphocytes, were diminished
after exposure to solitomab. Previous studies have sug-
gested that TIL and TAL associated with tumors or as-
citic fluids are frequently anergic and/or tolerogenic
towards autologous tumor cells [18–21]. The addition of
solitomab to cultures of EpCAM expressing CS and au-
tologous TAL appears to activate these tumor-anergic T
cells in pleural fluid causing a cytotoxic T-cell response
strong enough to eliminate resistant CS cells.
Solitomab, and other antibody/BiTE®-based therapies,
may be effective through either IV or intraperitoneal/
intrapleural administration because of the frequency of ex-
pression of EpCAM on the surface of CS combined with
its minimal expression on mesothelial type cells in the ab-
dominal or pleural cavity. EpCAM/CD3-bispecific anti-
body construct (MT110) is currently being explored in
phase 1 studies of patients harboring advanced stage
tumors [22]. A trifunctional anti-EpCAM antibody (catu-
maxomab/Removab®), administered intraperitoneally to
patients harboring ovarian carcinomas refractory to
salvage chemotherapy, decreases tumor burden, ascites
accumulation, and necessity of paracentesis [23]. These
data resulted in the approval of catumaxomab in Europe
for the treatment of chemotherapy refractory ovarian can-
cer. A drug with similar format as solitomab, blinatumo-
mab, has been approved in the US for the treatment of
Philadelphia chromosome-negative relapsed or refractory
acute lymphoblastic leukemia. Like solitomab, blinatumo-
mab activates T cell function through binding of CD3 and
is a bispecific antibody construct that is a CD19-directed
CD3 T-cell engager (BiTE®) [24–26].
Ovarian and uterine carcinosarcoma are aggressive tu-
mors that are difficult to treat initially and particularly in
the recurrent state. The data presented here demon-
strate that EpCAM is expressed in the majority of
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carcinosarcomas evaluated (80 %) and that solitomab ef-
fectively induced ADCC and significant tumor death in
carcinosarcoma cell lines expressing EpCAM that were
incubated with PBL. Solitomab, compared to control
BiTE®, caused an increase in the production of type 1 cy-
tokines and cytotoxic activity of tumor associated lym-
phocytes isolated from pleural fluid in CS harboring
patients and may increase recruitment as well as activa-
tion of CD4 and CD8+ T cells. Clinical trials should be
designed to assess the efficacy of solitomab as a novel
therapeutic approach in patients with chemotherapy re-
fractory carcinosarcoma.
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